跳至主要内容
临床试验/NCT01182519
NCT01182519已完成不适用

Association of Smoking, Lung Inflammation and Lung Metastases From Breast Cancer

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2010年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
400
试验地点
1
主要终点
The association between urinary PGE-M and the presence or absence of lung metastases

研究概览

简要总结

The purpose of this study is to find out if there is a link between cigarette smoking, inflammation and the spread of breast cancer to the lung. We think that women who are current or former smokers may be at increased risk for breast cancer spreading to the lung compared to women who have never smoked. Smoking causes inflammation in the lung in some women. Researchers at Memorial Sloan-Kettering (MSKCC) think that smoking-related lung inflammation may increase the chance of breast cancer spreading to the lung. In order to find out whether inflammation plays a role in breast cancer spreading to the lung, we will measure a urinary marker of lung inflammation. This will allow us to determine if this marker is more commonly elevated in women with breast cancer that has spread to the lung compared to those without breast cancer in the lung. We will also collect DNA from blood to have the opportunity to determine if there are differences in DNA in women with or without breast cancer that has spread to the other sites including the lung. We will also collect blood to determine if we can identify risk factors for the spread of breast cancer to the lungs.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Registered patient at MSKCC
  • Histologically proven breast cancer. It is not necessary that pathology be reviewed at MSKCC
  • Age ≥18 years Group 1 (A and B)
  • Diagnosed with metastatic breast cancer on biopsy or imaging study.
  • Patients will be considered to have lung metastases, and will be assigned to group 1A if any of the following criteria are met, otherwise patients will be assigned to group 1B "No known Lung Metastases," Biopsy-proven lung metastasis.
  • Pleural effusion with cytologic evidence of malignancy.
  • Pleural effusion, exudative in character, without alternative explanation and attributed, in the opinion of the clinician to metastatic disease.
  • Symptoms attributable to lung metastases and a radiological pattern interpreted by a radiologist as suspicious for metastatic disease.
  • Any pulmonary nodule on chest radiograph, CT scan, PET-CT or MRI, which is interpreted by the clinician and radiologist to be metastatic in etiology, whether or not a biopsy was performed, and regardless of symptoms.
  • A radiographic pattern interpreted by a radiologist as consistent with lymphangitic carcinomatosis.
  • Group 2 (Controls)
  • History of early breast cancer and currently no evidence of disease

排除标准

  • Inability to provide written informed consent.
  • Inability to complete smoking and NSAID questionnaire.
  • Steroid use within the previous 4 weeks.
  • Radiotherapy to the breast, chest wall or axilla within the previous 3 months.
  • Men with breast cancer.

结局指标

主要结局

The association between urinary PGE-M and the presence or absence of lung metastases

时间窗: 2 years

in patients with breast cancer

次要结局

  • The putative link between smoking and site-specific metastases from breast cancer(2 years)
  • Polymorphisms for genes linked to inflammation (germ line DNA SNPs)(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验